Almac said that the assay will be used in a clinical study of repotrectinib (TPX-0005), an investigational, next-generation tyrosine kinase inhibitor.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The next-generation sequencing assay is intended for use in identifying patients with ROS1, NTRK1-3, and ALK gene fusions in advanced solid tumors.
Almac is developing the assay to enroll patients for clinical trials used to develop repotrectinib, an investigational tyrosine kinase inhibitor.
The test is intended to identify patients with ROS1, NTRK, and ALK gene fusions for treatment with TP's investigational drug repotrectinib.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The collaboration will streamline patient sample analysis to determine whether they should be included in clinical trials for molecularly targeted treatment.
A brief recap of Genetics/Genomics news the week of Oct 7, 2016: SEC, Exact Sciences, Eurofins MWG Operon, Almac Group, California Blood organizations, Stat-Diagnostica, and Biofortuna
The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.
The deal allows UK-based Almac to develop NGS assays on the Illumina MiSeqDx instrument.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.